NO934776L - Rensing av rekombinant apoliproteiner E fra bakterier - Google Patents

Rensing av rekombinant apoliproteiner E fra bakterier

Info

Publication number
NO934776L
NO934776L NO934776A NO934776A NO934776L NO 934776 L NO934776 L NO 934776L NO 934776 A NO934776 A NO 934776A NO 934776 A NO934776 A NO 934776A NO 934776 L NO934776 L NO 934776L
Authority
NO
Norway
Prior art keywords
apoe
purification
recombinant
analog
fatty acids
Prior art date
Application number
NO934776A
Other languages
English (en)
Other versions
NO934776D0 (no
Inventor
Ruth Lifshitz
Meir Fischer
Benjamin Greenman
Daniel Bartfeld
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NZ238813A external-priority patent/NZ238813A/en
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Publication of NO934776D0 publication Critical patent/NO934776D0/no
Publication of NO934776L publication Critical patent/NO934776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Fremgangsmåter for rensing av humant ApoE eller analog derav fra rekomblnante bakterielle celler med minimal protein aggregasjon og degradering i løpet av rens- ningsprosessen er beskrevet. Tilsetning av nøytrali- serende fettsyrer til mediet l løpet av celle- ødeleggelsen og anvendelse av en ikke-ionisk detergent iløpet av rensningsprosessen er beskrevet. Videre er en fremgangsmåte for å øke produksjonen av ApoE eller analog derav i en bakteriell vert ved tilsetning til dyrkningsmediet næytraliserende fettsyrer, fettsyre- forløpere, triglycerider, triglyceridforløpere eller acetat samt farmasøytiske og diagnostiske anvendelser av ApoE analogen, er beskrevet.
NO934776A 1991-06-26 1993-12-22 Rensing av rekombinant apoliproteiner E fra bakterier NO934776L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1991/004553 WO1993000443A1 (en) 1991-06-26 1991-06-26 Purification of recombinant apolipoprotein e from bacteria
NZ238813A NZ238813A (en) 1991-06-26 1991-07-01 Production and purification of apolipoprotein e (apo e) and its use
US08/333,872 US5525472A (en) 1991-06-26 1994-11-03 Method for production and purification or recombinant Apolipoprotein E from bacteria

Publications (2)

Publication Number Publication Date
NO934776D0 NO934776D0 (no) 1993-12-22
NO934776L true NO934776L (no) 1994-02-17

Family

ID=27353645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934776A NO934776L (no) 1991-06-26 1993-12-22 Rensing av rekombinant apoliproteiner E fra bakterier

Country Status (3)

Country Link
US (1) US5525472A (no)
NO (1) NO934776L (no)
WO (1) WO1993000443A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005190A1 (en) * 1993-08-12 1995-02-23 Bio-Technology General Corp. Method of inhibiting kaposi's sarcoma
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6277874B1 (en) * 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
CA2277199A1 (en) * 1996-09-11 1998-03-19 Hans Ageland A process for purifying apolipoproteins and a composition for use in the process
DE69720786T2 (de) * 1996-09-11 2003-11-06 Pharmacia Ab Verfahren zur reinigung von apolipoproteinen
JP2003525883A (ja) * 2000-03-03 2003-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US6555391B1 (en) * 2000-08-15 2003-04-29 Baxter International, Inc. Methods of conditioning an affinity resin after storage
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
CN1312273C (zh) * 2002-09-30 2007-04-25 中国科学院沈阳应用生态研究所 一种光合细菌培养基用添加剂
DE10309691B4 (de) * 2003-02-28 2018-10-04 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Gewinnung von löslichen Proteinen aus der Biomasse rekombinanter Mikroorganismen
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
CN100586958C (zh) * 2006-12-20 2010-02-03 上海莱士血液制品股份有限公司 高纯度载脂蛋白a-i的制备方法
US8013122B2 (en) * 2006-12-20 2011-09-06 Kieu Hoang Method of purifying apolipoprotein A-1
US8324366B2 (en) * 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
KR102344392B1 (ko) 2008-11-10 2021-12-28 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
NZ621981A (en) 2009-05-05 2015-09-25 Tekmira Pharmaceuticals Corp Lipid compositions
EA201791744A3 (ru) 2009-06-10 2018-07-31 Арбутус Биофарма Корпорэйшн Улучшенная липидная композиция
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120245076A1 (en) * 2009-09-03 2012-09-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering rnai using apoe
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
ES2749426T3 (es) 2009-12-18 2020-03-20 Univ British Columbia Métodos y composiciones para administración de ácidos nucleicos
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
DK2575764T3 (en) 2010-06-03 2017-08-07 Alnylam Pharmaceuticals Inc BIODEGRADABLE LIPIDS FOR THE ACTIVATION OF ACTIVE AGENTS
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN103370054A (zh) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
EP2663548B1 (en) 2011-01-11 2017-04-05 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
CN103443123B (zh) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4656132A (en) * 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
US4943527A (en) * 1985-10-04 1990-07-24 California Biotechnology Inc. Mature apoai protein production under serum free culturing conditions
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum

Also Published As

Publication number Publication date
US5525472A (en) 1996-06-11
WO1993000443A1 (en) 1993-01-07
NO934776D0 (no) 1993-12-22

Similar Documents

Publication Publication Date Title
NO934776L (no) Rensing av rekombinant apoliproteiner E fra bakterier
DE3152001C2 (no)
LU91704I2 (fr) Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)
ATE188255T1 (de) Von blutplättchen abstammende biologisch aktive analoga eines wachstumsfaktors in eukaryotischen zellen
KR900700617A (ko) 뼈 및 연골 유도 조성물
ATE321141T1 (de) Verfahren zur herstellung eines rekombinanten polypeptids unter hinzufügung eines chymotrypsinhemmstoffes zum zellkulturmedium
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
ATE60362T1 (de) Verfahren zur herstellung von oligosaccharide enthaltenden produkten aus biomassen, diese oligosaccharide enthaltenden produkte und ihre verwendung.
DE3880380D1 (de) Fermentative herstellung von dicarbonsaeuren.
MX9605082A (es) Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
ES2288976T3 (es) Esterasa estereoselectiva de aspergillus oryzae.
DE68928634D1 (de) Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität
Foster et al. Improved methodologies for the isolation and purification of tropoelastin
FR2546905B1 (fr) Procede de prevention et traitement des arrets de fermentation en vinification
SU460292A1 (ru) Способ осахаривани крахмалистого сырь ферментными препаратами
DE2418716C3 (de) Verfahren zur Reinigung von Pilzalpha-Amylase
Yamamoto Maltase action of bacterial α-amylase
JPS5876085A (ja) 地衣植物組織培養方法
JPH0597685A (ja) 動物細胞生育促進剤
Barnett Anaerobic filtration of waste waters arising from the production of bakers' yeast: a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Biotechnology at Massey University
JPS5618591A (en) Production of substance capable of differentiation and multiplication of stem cells of human granulocyte
JPS5682095A (en) Purification of fatty acid produced through fermentation process
KR940701451A (ko) 박테리아로 부터 재조합 아포리포 단백질의 정제
CH588284A5 (en) Tuberculin active proteins and peptides prepn - from tubercle bacillus
JPS5639780A (en) Purification of glutathioneperoxidase